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Abstract
Background It is well acknowledged that HPV testing
should not be performed at young age and at short inter-
vals. Cytological screening practices have shown that over-
screening, i.e., from a younger age and at shorter intervals
than recommended, is hard to avoid. We quantified the
consequences of a switch to primary HPV screening for
over-screened women, taking into account its higher sen-
sitivity but lower specificity than cytology.
Methods The health effects of using the HPV test instead
of cytology as the primary screening method were deter-
mined with the MISCAN-Cervix model. We varied the age
women start screening and the interval between screens. In
the sensitivity analyses, we varied the background risk of
cervical cancer, the HPV prevalence, the discount rate, the
triage strategy after cytology, and the test characteristics of
both cytology and the HPV test.
Results For women screened 5 yearly from age 30, 32
extra deaths per 100,000 simulated women were prevented
when switching from primary cytology to primary HPV
testing. For annual screening from age 20, such a switch
resulted in 6 extra deaths prevented. It was associated with
9,044 more positive primary screens in the former scenario
versus 76,480 in the latter. Under all conditions, for women
screened annually, switching to HPV screening resulted in
a net loss of quality-adjusted life years.
Conclusion For over-screened women, the harms asso-
ciated with a lower test specificity outweigh the life years
gained when switching from primary cytology to primary
HPV testing. The extent of over-screening should be con-
sidered when deciding on inclusion of primary HPV
screening in cervical cancer screening guidelines.
Keywords Uterine cervical neoplasms  Computer
simulation  Early detection of cancer  Papanicolaou test 
Human papillomavirus DNA tests
Introduction
In several Western countries, cytological screening has
considerably reduced the cervical cancer incidence and
mortality over the past four decades [1]. Nevertheless, even
in countries with a nationwide screening program, women
still die from cervical cancer. Although most deaths occur
after age 30 and in women who did not adequately par-
ticipate in screening, some deaths occur at young age and
in women who recently received a negative test result
(which suggests it was false negative) [2–4]. Therefore,
clinicians may tend to screen more frequently than rec-
ommended [5].
Ever since infection with the human papillomavirus
(HPV) was found to be a necessary condition for devel-
oping cervical cancer [6, 7], testing for the presence of
high-risk HPV types (i.e., carcinogenic types) has received
much attention. A summary of meta-analyses estimated
that the HPV test has a 23 % (95 % CI 13–33 %) higher
sensitivity, but a 6 % (95 % CI 4–8 %) lower specificity
than cytology for detecting high-grade lesions and cervical
cancer [8]. Cost-effectiveness analyses based on these
findings have shown that in well-controlled screening
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situations primary HPV screening is likely to be more
effective, as well as more cost-effective than primary
cytology [9, 10]. Therefore, many countries are considering
a switch from primary cytology to primary HPV screening.
In the USA, co-testing (i.e., cytology combined with HPV
testing) is already recommended, and Australia and the
Netherlands are preparing a switch from primary cytology
to primary HPV screening [11–13].
For primary cytology, it is known that over-screening,
here defined as screening from a younger age or at shorter
intervals than recommended, is neither required to detect
progressive lesions in an early phase nor desired as it
detects many regressive lesions. Unavoidably, it also
involves more false-positive test results, adding to the
psychological stress women may experience from having a
positive test and being referred for colposcopy [14]. In
addition, the costs of over-screening are substantial,
amounting to approximately 0.5–1 billion USD per year for
the US healthcare system, while yielding little or no health
gains [15].
Because of its lower specificity to detect clinically rel-
evant lesions, avoiding over-screening is even more
essential for HPV screening than for cytology screening.
The vast majority of HPV infections clear spontaneously,
especially at young age [16]. Detecting these infections
leads to unnecessary triage situations or referrals to col-
poscopy. For over-screened women, switching to HPV (co-
)testing may therefore do more harm than good.
Guidelines driven by rational decision making tend to
restrict cytology screening—and HPV screening even more
so. The US guidelines currently recommend cervical
screening in women aged 21–65 years with an interval of 3
or 5 years (dependent on both age and test) [17]. In
European guidelines, primary HPV screening is recom-
mended for women aged C35 and discouraged for those
below the age of 30 [18]. In the Netherlands, primary HPV
screening will be offered from age 30 to 65 every
5–10 years, and in Australia from age 25 to 69 every
5 years [11, 13]. Unfortunately, also for HPV screening,
having well-considered screening policy recommendations
will not guarantee that women are screened accordingly.
A recent US study showed that over 68 % of physicians
would recommend another cytological test in 1 or 2 years
where the guidelines recommend a 3-year interval [19].
After a negative co-test, 67–94 % of clinicians recom-
mended a shorter screening interval than suggested by US
guidelines [20]. Several European countries also have
reported considerable over-screening [21]. In summary,
large proportions of women are being over-screened with
cytology, and this is likely to continue when HPV
screening is implemented.
Notwithstanding these facts, HPV testing is, for good
reasons, increasingly often included in primary screening
recommendations. However, despite its lower specificity,
we are unaware of intensified efforts to minimize the level
of over-screening. In this study, we aim to quantify the
harms and benefits of introducing primary HPV screening
for women with diverse screening behaviors, age of first
screen ranging from 20 to 30 years, and screening interval
from 1 to 5 years. These scenarios cover both recom-
mended schedules and observed levels of over-screening.
The results of this study show the effects of introducing
HPV screening for over-screened women, as well as for
those who adhere to guidelines. Although the model was
based on Dutch data, the resulting outcomes are important
for all over-screened women, regardless of where they live.
Since it seems too early to draw conclusions on the effect
of switching to HPV screening in over-screened women
who have been vaccinated, this analysis only considers
unvaccinated cohorts.
Methods
Health effects of different screening scenarios were esti-
mated using the MISCAN-Cervix model, which is descri-
bed in more detail in the model profile (see Supplement)
[22].
MISCAN-Cervix model
MISCAN-Cervix is a microsimulation model in which a
large study population with individual life histories is
generated. In all of the analyses presented here, we simu-
lated a 20-year-old cohort of 100 million women with life
expectancy as observed in the Netherlands [23], which was
not affected by HPV vaccination (neither directly nor
through herd immunity). A fraction of these women will
acquire HPV infections and/or develop cervical intraep-
ithelial neoplasia (CIN) lesions. If these precursors pro-
gress to cervical cancer, the result may be death. Screening
can detect the disease, which can then be treated at an
earlier stage. As a result, cervical cancer death may be
prevented or postponed.
In the model, the disease development is in seven
sequential stages: high-risk HPV infection, three preinva-
sive stages (CIN grades I, II, and III), and three invasive
stages (International Federation of Gynecology and
Obstetrics (FIGO) stages IA, IB, and II or worse). While
preinvasive and FIGO IA stages can be diagnosed only by
screening, because at these stages the women are assumed
to be symptom-free, FIGO IB or worse can also be clini-
cally diagnosed. Because precursors are usually not pro-
gressive [24], over 90 % of modeled HPV infections clear
without ever resulting in neoplasia and most preinvasive
lesions regress spontaneously. In the hypothetical situation
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without competing other-cause mortality, undetected pre-
clinical invasive neoplasia will always progress to clinical
cancer. CIN grades I and II can develop in the absence of a
high-risk HPV infection; in that case, the lesion will always
regress. CIN grade III or worse can only develop if a high-
risk HPV infection is present.
Triage strategies
For primary HPV screening and primary cytology, we used
a cost-effective triage strategy, as published previously [9].
Primary cytological test results classified as atypical
squamous cells of undetermined significance (ASCUS) or
low-grade squamous intraepithelial lesion are immediately
followed by an HPV test using the same material. A pos-
itive primary HPV test is immediately followed by cytol-
ogy using the same material. If no cytological
abnormalities are found, another cytological test is per-
formed after 6 months.
Although the latter strategy will also be implemented in
the Dutch screening program in 2017, triage strategies were
not selected based on guidelines or current practice.
Instead, we decided to select strategies based on cost-ef-
fectiveness, such that inefficiencies in triage strategies
would not dilute or exaggerate the effect of switching to
HPV screening. The triage practices of over-screened
women are unknown and might be very heterogeneous. It
seems unlikely that women, who do not follow primary
screening guidelines, do follow the exact triage recom-
mendations. We therefore chose to simulate a relatively
simple triage strategy for both primary tests and to focus on
the number of positive primary tests (i.e., those that require
follow-up) instead of on the number of triage tests.
Screening scenarios
We simulated 12 cohorts with different screening behav-
iors, varying the age at which women start screening (20,
25, or 30 years) and the frequency with which they get
tested (every 1, 2, 3, or 5 years). In all scenarios, screening
was assumed to end at or before the age of 65 [17, 25]. The
resulting outcomes are only relevant for women having the
screening behavior as modeled and should not be translated
to an entire population.
Assumptions for screening and treatment
Table 1 presents the base case assumptions for screening.
We assumed the sensitivity of cytology (that is, the prob-
ability that the result is at least ASCUS) to be 40 % for true
stage CIN grade I, 50 % for CIN grade II, and 75 % for
CIN grade III or cancer [26]. In the model calibration, the
sensitivity of testing for at least high-grade squamous
intraepithelial lesion (HSIL), the cytological cutoff for
referral to colposcopy, and therefore for detection, was
estimated to be 4 % for CIN grade I, 18 % for CIN grade
II, 56 % for CIN grade III, and 60 % for cervical cancer.
Furthermore, the specificity of cytology was estimated to
be 97.6 % based on Dutch data [27]. Based on the observed
difference in CIN grade III or cancer detection rates
between cytology and the HPV test, we assumed the sen-
sitivity of the HPV test to be 94 % for a high-risk HPV
infection [28]. As we assumed that cervical cancer can only
develop if an HPV infection is present, the sensitivity for
cervical cancer is also 94 %. The overall sensitivity for
CIN lesions is lower and depends on the age-specific
prevalence of HPV infections in CIN lesions. In the model,
the specificity for detecting high-risk HPV infections was
assumed to be 100 %. A probable (but unknown) lack of
specificity was accounted for by the inclusion of fast-
clearing infections, in concordance with HPV clearing
studies [29, 30].
Detection and management of preinvasive lesions,
including treatment if necessary, were assumed to lead to a
100 % cure rate. However, new HPV infections and
recurring CIN lesions after CIN treatment cannot be
excluded. For invasive cancer, we determined age-specific
and stage-specific survival probabilities based on data from
the Netherlands Cancer Registry [31]. Since cancers
detected by screening are usually at a less advanced stage
than clinically diagnosed ones, women have a higher
chance to survive them. If an invasive cancer is screen-
detected, the probability to die from cervical cancer is
reduced by 89.4, 50, and 20 % when detected in FIGO
stages IA, IB, and II or worse, respectively.
Table 2 presents the utility losses assumed in the base
case scenario. A small (psychological) loss in quality of
life is assumed for attending a screen (including waiting for
the result) and for being in triage (including attending
follow-up screenings). Larger losses in quality of life are
assumed for being diagnosed and treated for CIN or cancer
and for having a terminal stage of cervical cancer. We
based the utility losses on nationally and internationally
published data [32–35].
Base case analysis
For every scenario, we first estimated health effects of both
primary cytology and primary HPV testing as compared to
the situation without screening. Then, differences in health
effects between these two interventions were explored. A
first indication of the harm–benefit balance of introducing
primary HPV testing is given by the number of additional
positive primary screens (i.e., at least ASCUS for cytology
screening and HPV positive for HPV screening) that is
required to prevent one additional cervical cancer death. As
Cancer Causes Control (2016) 27:569–581 571
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women with a positive primary screen require follow-up in
terms of triage or colposcopy, we refer to this outcome
measure as ‘‘Number Needed to Follow-up’’ or NNF.
Comparing the life years lost to cervical cancer between
the two interventions yields the number of life years gained
by switching to the more sensitive primary HPV testing.
Similarly, the difference in total disutility due to screening
and treatment caused by these interventions can be com-
puted. As the number of quality-adjusted life years
(QALYs) gained combines these positive and negative
Table 1 Base case model inputs and variations in the sensitivity analyses
Parameter Base case value Alternative value(s)
Background risk of cervical cancer mortality 5 per 100,000 life years 10 per 100,000 life years
HPV prevalence in women without CIN grade II or worsea Low Highb
Sensitivity of cytology
Probability of at least ASCUS (at least triage) for:
CIN grade I 40 % [26] 32 %
CIN grade II 50 % [26] 40 %
CIN grade III or worse 75 % [26] 60 %
Probability of at least HSIL (referral for colposcopy) for:
CIN grade I 4 %c 3 %
CIN grade II 18 %c 14 %
CIN grade III 56 %c 45 %
Cervical cancer 60 %c 48 %
Specificity of cytology (CIN grade I or worse) 97.6 %c 95.2 %
Sensitivity of HPV testd 94 % [28] 85 % [8], 100 % [8]
Specificity of HPV test 100 %e Not varied as suchf
Discounting 3 % [36] 0 %, 5 %
HPV human papillomavirus, CIN cervical intraepithelial neoplasia, ASCUS atypical squamous cells of undetermined significance, HSIL high-
grade squamous intraepithelial lesion
a Depends on age, age dependency was not varied
b The number of false-positive referrals to colposcopy and CIN grade I lesions was doubled
c Value was determined in model calibration
d Probability to detect an HPV infection, regardless of whether a CIN lesion or cancer is present
e A possible lack of specificity was modeled by including fast-clearing HPV infections
f As a lower specificity of the HPV test corresponds with a higher prevalence of harmless HPV infections in the model, this parameter was not
varied
Table 2 Model inputs
regarding the utility loss due to
screening, treatment, and
terminal care
Disutility Duration Quality-adjusted time lost
Screening [34]
Primary screening 0.005 2 weeks 2 hours
Being in triage 0.005 0.5 yeara 22 hours
False-positive referral 0.005 0.5 year 22 hours
Treatment of preinvasive lesions [33]
CIN grade I 0.03 0.5 year 6 days
CIN grade II or III 0.07 1 year 26 days
Cancer treatment [32, 33] and terminal care [35]
FIGO stage I 0.062 5 years 4 months
FIGO stage II? 0.280 5 years 17 months
Terminal care 0.740 1 year 9 months
CIN cervical intraepithelial neoplasia, FIGO International Federation of Gynecology and Obstetrics
a Time between primary and triage test is 6 month
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effects of screening, this outcome measure was used to
compare the total health effects of primary HPV screening
with those of primary cytology. Health effects were dis-
counted to the year in which all women are 20 years old,
using an annual rate of 3 % [36].
Sensitivity analyses
Some model parameters may have a non-negligible level of
uncertainty, while others differ among countries or geo-
graphical regions. In one-way sensitivity analyses, we
varied these types of parameters, covering for high-income
countries, if they would influence the difference in health
effects between primary HPV screening and primary
cytology (Table 1).
Among Dutch women, the assumed background risk of
dying from cervical cancer is relatively low (5 deaths per
100,000 life years). We have doubled this risk to determine
the effects for countries with a higher risk.
To observe the effect of a higher prevalence of harmless
HPV infections, we have doubled the number of referrals
that did not result in the detection of a clinically relevant
lesion (i.e., CIN grade II or worse). Detecting more
harmless HPV infections implicitly corresponds with a
lower clinically relevant specificity of HPV testing.
Presumably, the high level of quality assurance in the
Netherlands contributes to a relatively high quality of
cytology compared to less controlled situations. To explore
the impact of switching to HPV testing for settings with a
lower quality of cytology, the sensitivity of cytology in
both primary and triage testing was reduced by 20 % in one
of the sensitivity analyses. In another sensitivity analysis,
the lack of specificity of cytology in both primary and
triage testing was doubled from 2.4 to 4.8 %.
Some uncertainty exists about the sensitivity of the HPV
test, which may also vary between tests and situations. A
summary of meta-analyses found that the relative sensi-
tivity of the HPV test as compared to cytology is 1.23
(95 % CI 1.13–1.33). Based on this confidence interval, the
sensitivity of the HPV test was assumed to be 85 % in one
of the sensitivity analyses and 100 % in another [8]. As
these are assumed probabilities to detect an HPV infection,
and women with a CIN lesion are not necessarily HPV
infected, the sensitivity for CIN lesions is still lower than
100 % in the latter scenario.
In another sensitivity analysis, the triage strategy after a
positive cytological test was adjusted to reflect current
Dutch screening guidelines. According to these guidelines,
women with HSIL are directly referred for colposcopy and
women with ASCUS or low-grade intraepithelial lesion
(LSIL) are invited for cytology and HPV triage after
6 months. Women testing HSIL or ASCUS/LSIL and HPV
positive at this point in time will be referred for
colposcopy, and women testing either ASCUS/LSIL or
HPV positive will be invited for another cytological test at
18 months.
Lastly, as reported discount rates vary from 0 to 5 %, we
also present the health effects when using an annual dis-
count rate of 0 % and of 5 %.
Results
Base case analysis
For the 12 different screening scenarios considered,
Table 3 shows the impact of replacing primary cytology
with primary HPV screening. The numbers are based on
the undiscounted results of primary cytology and primary
HPV screening compared to the situation without screen-
ing, as displayed in Supplementary Tables 1 and 2,
respectively. Although in practice, it is very unlikely that
the start age is well controlled, while the screening interval
is not, we first discuss the effects of switching to HPV
testing in women who start screening at age 30 and have
repeated testing at intervals that are either recommended or
shorter than recommended. Then, we discuss the effects of
switching for women who are not only screened more
frequent than recommended, but also from a younger age.
Frequent screening from age 30
For 5-yearly screening starting at age 30, replacing primary
cytology with primary HPV screening reduced the number
of cervical cancer deaths by 32 per 100,000 simulated
women, which was a reduction of 27 % (Fig. 1; Table 3).
This reduction was achieved at the expense of 9,044 more
positive primary screens per 100,000 women (?34 %),
resulting in 2,572 more referrals to colposcopy (?29 %).
With annual screening in the same age range, switching to
primary HPV screening would prevent only 7 extra deaths
per 100,000 women (-9 %), while positive primary
screens would increase by 14,271 (?14 %) and referrals to
colposcopy by 3,477 (?19 %). The (discounted) NNF was
769 in the first scenario versus 11,880 in the latter, more
intensive one (Table 4).
Frequent screening from age 20
With annual screening starting at the age of 20 instead of
30, switching from primary cytology to primary HPV
screening resulted in similar benefits [i.e., six additional
deaths prevented per 100,000 women (-9 %)]. However,
the number of women with a positive screen test increased
by 76,480 instead of by 14,271 per 100,000 women. The
NNF equaled 60,133, which was more than 5 times the
Cancer Causes Control (2016) 27:569–581 573
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NNF of switching in case of annual screening from age 30
and more than 78 times the NNF of switching in case of
5-yearly screening from age 30.
Changes in QALYs
Table 5 shows the QALYs gained (or lost) by switching
from primary cytology to primary HPV screening for the
diverse screening behaviors. Under base case assumptions,
a substantial number of QALYs were gained for women
who were screened every 5 years from age 30. For more
intensively screened women, the benefit of switching to
HPV screening was uncertain. For women screened annu-
ally or biennially from any age, or triennially from age 20
or 25, replacing primary cytology with primary HPV test-
ing even resulted in a net health loss.
Sensitivity analyses
In all sensitivity analyses, primary HPV screening pre-
vented more cervical cancer deaths than did primary
cytology. In most scenarios, this occurred at the expense of
more positive screens, and the NNF increased quite rapidly
with the intensity of the screening scenario (Table 4). Only
when the specificity of cytology was assumed to be lower
(95.2 % instead of 97.6 %), for some levels of over-
screening, the number of positive screens decreased with
the shift to primary HPV testing. The discount rate
appeared to have the largest impact on the NNF.
In the sensitivity analyses, switching to primary HPV
testing resulted in fewer QALYs gained in the case of more
intensive screening. Overall, for a given level of over-
screening, whether QALYs were gained or lost did not vary
substantially among the sensitivity analyses. Generally,
switching was favorable for women screened every 5 years
and unfavorable for those screened annually or biennially.
However, when the background risk of cervical cancer
mortality was increased, when cytology was triaged as is
currently recommended in the Dutch screening program or
when health effects were not discounted, switching to HPV
screening also resulted in QALYs gained for women
screened biennially from age 30. For women screened
every 5 years from age 20, QALYs were lost when the
HPV prevalence was increased and when results were
discounted at an annual rate of 5 %.
Discussion
Even in countries with carefully constructed screening
guidelines, women may be over-screened. As for over-
screened women the risk of cervical cancer is already
strongly reduced with primary cytology, the gains of
switching to primary HPV screening are expected to be
relatively small. Indeed, our analysis predicted that while
switching would prevent 32 deaths per 100,000 women
who are screened every 5 years, only 6–7 deaths would be
averted in those screened annually. In the latter group, the
increase in positive tests and subsequent follow-up proce-
dures even resulted in a net loss in health.
Because the same conclusion was reached in all of the
sensitivity analyses, it is likely generalizable to other
Fig. 1 Simulated increase in
lifetime number of deaths from
cervical cancer prevented (left
axis) and positive primary
screens (right axis) when
primary cytology is replaced
with primary HPV screening.
The increase in positive primary
tests is split up in referrals to
colposcopy (dark gray) and
non-referrals to colposcopy
(light gray). Undiscounted
results for different start ages
and intervals of screening are
given per 100,000 women
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developed countries. The lower the ratio of HPV preva-
lence to cervical cancer mortality risk, the less harmful the
HPV testing will be for over-screened women. The sensi-
tivity analysis in which we doubled the lifetime risk of
dying from cervical cancer showed that it would still be
harmful if this ratio would be twice as low as in the
Netherlands though. In countries with an even lower HPV
prevalence to cervical cancer mortality risk ratio, switching
to HPV testing might be beneficial for over-screened
women. In the USA, however, both HPV prevalence and
cervical cancer mortality are comparable to the Nether-
lands [37, 38]. In most European countries, cervical cancer
mortality is higher [39], but HPV prevalence is also (up to)
twice as high [38].
Obviously, the goal of a cancer screening program is to
decrease the disease’s incidence and mortality rate.
Because in every simulated scenario switching from pri-
mary cytology to primary HPV screening reduced the
number of cervical cancer cases and deaths, one could
argue that primary HPV screening should always be pre-
ferred. This would indeed be true if being in triage, being
referred for colposcopy, and being treated for CIN would
not be associated with losses in quality of life. However,
the health-related burden of these events is a drawback of
screening that should not be overlooked [40, 41].
A number of randomized controlled trials (RCTs) have
compared primary cytology screening to either HPV
screening alone or HPV screening combined with cytology
[42–45]. In these RCTs, HPV screening resulted in a higher
detection rate of CIN lesions and an improved protection
against cervical cancer [46]. CEAs based on these findings
showed that primary HPV screening with an interval of at
least 3 years is cost-effective for women above age 30 [9,
47]. We showed that the effectiveness is questionable if
this cannot be guaranteed. In this regard, data from a US
population-based registry showed that recommending
3-yearly cytology screening resulted in a median time
between two consecutive smears of 1.87 years in 2011
[48]. There is no reason to assume that guidelines regarding
primary HPV screening would be followed more closely.
In fact, a study from 2010 found a lower adherence to
guidelines after a negative co-test as compared to after a
negative cytological test [19]. Although co-testing is
intended for women who want to extend their screening
interval from 3 to 5 years, many clinicians provide it on an
annual basis [19].
Switching to HPV screening could be considered more
effective for women with that level of over-screening for
which HPV screening was associated with a net health
benefit, but this would not necessarily be more cost-ef-
fective. However, the decision to include primary HPV
screening in national screening guidelines should take into
account its population-level cost-effectiveness. If only a
relatively small number of women are over-screened, then
switching to HPV screening may well be (very) cost-ef-
fective on a population level. In the Netherlands, given the
small number of smears taken outside the screening pro-
gram [49], it is expected to be cost-effective.
Strengths and limitations
Even though earlier research showed that primary HPV
screening is more cost-effective than primary cytology for
women who adhere to screening guidelines [10, 50], this is
the first study to quantify its harms and benefits for over-
screened women. As over-screening practices are likely to
remain, these results are relevant to any country consid-
ering recommending primary HPV screening, either alone
or as a co-test.
Our study also has some limitations. First of all, our
model is based on Dutch data. Although it might have been
better to adjust the model for every single country, we did
vary those country-specific parameters that would influence
the conclusion. For example, we increased the HPV
prevalence level to estimate effects for high HPV preva-
lence countries such as Denmark [51]. We did not modify
the prevalence age distribution as the peak between the
ages of 20 and 30 has also been observed in other European
countries and in the USA [51, 52].
Although we varied test characteristics to explore the
effect of switching to HPV screening for different settings,
the ranges considered are not representative for low- and
middle-income countries, where sustaining cytology pro-
grams of sufficient quality is often difficult [53, 54]. As the
test characteristics are only one of many factors that may
be different in those countries, separate analyses are needed
for these situations.
Meta-analyses have shown that removal of CIN lesions
carries an increased risk of having preterm births [55, 56].
We did not include this potential harm because estimates of
the impact on a woman’s quality of life are unavailable. If
we would have accounted for this in our analyses, in over-
screened women even more QALYs would have been lost
by switching to primary HPV screening.
Although there are numerous possible triage strategies
for cytology and HPV testing, in the base case analysis we
only considered two that were found to be cost-effective in
a previous analysis [9]. In a sensitivity analysis, we did
explore the impact of switching from the less efficient
cytology screening strategy that is currently recommended
in the Netherlands to the cost-effective HPV screening
strategy that will be implemented in 2017. When these less
efficient cytology practices were assumed, switching to
HPV testing was obviously more beneficial. Nevertheless,
it still resulted in a net health loss for women screened
biennially from age 20 to 25 or triennially from age
578 Cancer Causes Control (2016) 27:569–581
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20 (effects for annually screened women were not evalu-
ated for this triage strategy). If future triage practices
would be much more efficient than current ones, then
switching to HPV testing might be considered beneficial
for over-screened women, but this would be due to more
efficient triage procedures rather than to an improved
performance of the primary test.
Lastly, we did not consider a co-testing strategy, which
is already recommended in the USA for women aged
30–65 years [12, 17, 57]. Co-testing results in more screen
positives than does primary HPV screening because HPV
negative smears can still be cytology positive. From results
of an RCT performed in the Netherlands, where women
aged 30–60 years are screened every 5 years, we calcu-
lated that the number of screen positives would be 33 %
higher with co-testing than with primary HPV screening
[28]. As a consequence, the number of screen-detected CIN
grade III lesions or cancer would be 7 % higher. In an RCT
performed in the UK, in which women aged 20–64 years
were screened with an interval of 2–4 years, the number of
screen positives would have been 46 % higher with co-
testing as compared to primary HPV screening, while the
number of screen-detected clinically relevant lesions (at
least CIN grade III) would have been only 3 % higher [58].
For intensively screened women, co-testing can potentially
prevent slightly more cervical cancer cases than primary
HPV screening, but the utility loss associated with the
additional positive screens probably outweighs these minor
gains. Therefore, co-testing is expected to be even more
harmful than primary HPV screening alone for over-
screened women.
Conclusion
We determined the pros and cons of replacing primary
cytology with primary HPV screening for women who are
over-screened, i.e., from a younger age and with a shorter
screening interval than recommended. Although in all
scenarios more deaths would be averted by screening pri-
marily with the HPV test, the negative effects outweighed
the benefits. We may conclude that irrespective of costs, it
is disputable to recommend primary HPV screening, either
alone or as a co-test, as long as a substantial part of the
population is still over-screened. A well-organized and
structurally monitored screening program, in which pri-
mary tests taken outside the program are not reimbursed by
the government, could help minimizing the number of tests
taken outside the program, thereby limiting the level of
over-screening [21, 59]. One may consider to first further
develop strategies to reduce over-screening or at least give
it high priority when issuing guidelines including primary
HPV screening.
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